Theradiag SA
PAR:ALTER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Theradiag SA
Long-Term Debt
Theradiag SA
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Theradiag SA
PAR:ALTER
|
Long-Term Debt
€1.6m
|
CAGR 3-Years
100%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Long-Term Debt
€1m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
4%
|
|
|
Biomerieux SA
PAR:BIM
|
Long-Term Debt
€330m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
Diagnostic Medical Systems SA
PAR:ALDMS
|
Long-Term Debt
€11.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
S
|
SMAIO SA
PAR:ALSMA
|
Long-Term Debt
€1.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Long-Term Debt
€102.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Theradiag SA
Glance View
Theradiag SA engages in the distribution, development and manufacturing of in vitro diagnostic and theranostics tests. The company is headquartered in Croissy-Beaubourg, Ile-De-France. The company went IPO on 2012-12-11. The firm develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. TheraDiags product offering consists of tests using a range of techniques (Elisa, rapid tests, immunofluorescence, Dot, immunochemical tests, molecular biology, etc.) as well as a range of automatic devices and solutions for high-speed diagnostics based on Luminexs Multiplex technology. The company has also developed a range of theranostic diagnostics commercialized under the Lisa-Tracker brand which provide monitoring of patients treated by anti-TNF monoclonal antibodies. TheraDiag is active in more than 30 countries, as an independent distributor.
See Also
What is Theradiag SA's Long-Term Debt?
Long-Term Debt
1.6m
EUR
Based on the financial report for Jun 30, 2023, Theradiag SA's Long-Term Debt amounts to 1.6m EUR.
What is Theradiag SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
44%
Over the last year, the Long-Term Debt growth was -1%. The average annual Long-Term Debt growth rates for Theradiag SA have been 100% over the past three years , 44% over the past five years .
